Biopharma News

Nov 02, 2017
By BioPharm International Editors
The companies will collaborate to develop and manufacture Grid’s lead therapeutic candidate for the treatment of solid tumors.
Oct 27, 2017
By BioPharm International Editors
AbbVie will pay a $205-million upfront payment and have the option to develop and commercialize two antibody targets globally.
Oct 27, 2017
By BioPharm International Editors
As part of the $900-million deal, Incyte will pay $150 million upfront to develop and commercialize an anti-PD-1 drug candidate from biopharmaceutical company, MacroGenics.
Oct 27, 2017
By BioPharm International Editors
The vaccine is approved for the prevention of shingles in adult patients aged 50 years and older.
Oct 26, 2017
By BioPharm International Editors
The company’s board of directors has appointed Aron Knickerbocker as the new president and CEO to succeed Lewis Williams, MD, PhD, effective Jan. 1, 2018.
Oct 26, 2017
By BioPharm International Editors
Inovio has reported results from a study with non-human primates that showed 100% effectiveness with a DNA vaccine the company is developing with the US Army.
Oct 26, 2017
By BioPharm International Editors
The collaboration aims to improve the pharmacokinetics of anti-C3 proteases developed by Catalyst to develop therapeutics for severe eye disorders.
Oct 25, 2017
By BioPharm International Editors
Russian biotechnology company BIOCAD plans to enter the European market with oncological and autoimmune medicines.
Oct 23, 2017
By BioPharm International Editors
The $72-million investment, part of a larger $850-million investment into its US operations, will allow the drugmaker to replace an outdated insulin vial-filling line and to upgrade technology at its Indianapolis manufacturing plant.
Oct 20, 2017
By BioPharm International Editors
The companies aim to use CureVac’s proprietary messenger RNA technology to develop and commercialize up to five potential cancer vaccine products.
native1_300x100
lorem ipsum